Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170704 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| SCHEMBL21232 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL27952288 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL3517185 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL12497423 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL841177 | 0.98 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2522634 | 0.96 | CHRNB2 (0.65) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28855199 | 0.94 | CYP2D6 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Methyl Alcohol SCHEMBL27512085 | 0.94 | CHRNB2 (0.58) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28855198 | 0.94 | CYP2D6 (0.61) | CHRNB2CHRNA7CHRNA4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773725-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | Loxo Oncology Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | claimed |
| EP-3700576-A1 | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR | Array Biopharma Inc. (US) | 2020-09-02 | — | — | EP | claimed |
| WO-2019191659-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-1554260-A1 | ARYLOXYALKYLAMINE DERIVATIVES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-6162417-A | Pyrrolo isoquinolines | EMORY UNIVERSITY (US) | 2000-12-19 | — | — | US | disclosed |
| US-5138062-A | Tranquilizers | PHILIP MORRIS INCORPORATED | 1992-08-11 | — | — | US | disclosed |
| US-5015741-A | Insecticides, aphidicides, psychological disorders, sedatives or tranquilizers | PHILIP MORRIS INCORPORATED (US) | 1991-05-14 | — | — | US | disclosed |
| US-4908450-A | Certain hexahydro-6-arylpyrrolo[2,1-A]isoquinolines | MCNEILAB, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| US-4837328-A | Stereoselective reaction for hexahydro-6-arylpyrrolo(2,1-A) isoquinolines | MCNEILAB, INC. (US) | 1989-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | CHRNB2 244/4885CHRNA7 741/4885CHRNA4 835/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | CHRNB2 752/4885CHRNA7 2245/4885CHRNA4 2251/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | CHRNB2 2973/4885CHRNA7 4291/4885CHRNA4 4564/4885 |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | TP53, NCOA3, NCOA1 | CHRNB2 2266/4885CHRNA7 3301/4885CHRNA4 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.